American pharmaceutical giant Pfizer has hiked its takeover bid for British rival AstraZeneca to $106.5 billion. CNBC's Catherine Boyle reports.
Surani Fernando, assistant editor of Biopharm Insight, discusses whether Pfizer's updated bid for AstraZeneca will placate the U.K. government's concerns over the mega-merger.
Pfizer is set to sweeten its bid for British pharma AstraZeneca. CNBC's Catherine Boyle reports on the developments.
Pfizer CEO Ian Read recently met with U.K.-based investors to discuss a second bid for AstraZeneca, valuing the firm at $106 billion, sources said.
As rivals assessed what Pfizer's play for AstraZeneca could mean for the industry, one aspect touched nearly everyone: What it could mean for a U.S. tax loophole.
Two proposals in Congress are taking aim at deadly superbugs. But it's not exactly clear to some experts just what the right medicine should be.
GlaxoSmithKline's sales fell 10%, highlighting the pressures behind last week's decision to trade more than $20 billion of assets with Novartis.
Ian Read, CEO of Pfizer, flew into London for a round of meetings with politicians and investors ahead of an expected fresh bid for AstraZeneca.
At the heart of Pfizer's pursuit of AstraZeneca is a shortage of products in its research pipeline, aggravated by a series of disappointing drug launches.
Brent Saunders, CEO of Forest Labs, discusses his company's acquisition by Ireland-based Actavis.
Rhenu Bhuller, Senior VP of Healthcare at Frost & Sullivan, says the rush of deals in the pharmaceutical sector may be a manifestation of the struggles that industry players are facing.
Sachin Shah, Analyst at Albert Fried & Company, says declining sales is one of the factors fueling the flurry of deals in the pharmaceutical sector.
Discussing Pfizer's push for a $100 billion deal for AstraZeneca, with Seamus Fernandez Leerink Partners managing director.
Alex Tarrant, M&A reporter at Dealreporter, discusses the implications of a potential deal between Pfizer and AstraZeneca.
CNBC's David Faber reports on Bill Ackman and Valeant's bid for Botox maker Allergan, and a look at how tax inversions are fueling pharma deals.
It's "too early to tell" if President Barack Obama's signature health care law is successful, Aetna CEO Mark Bertolini told CNBC.
CNBC's Meg Tirrell reports a Cowen analyst is suggesting Allergan buy ADHD drug maker Shire. The FMHR traders, provide perspective.
The chief executive of AstraZeneca, at the center of speculation of a $101 billion takeover, has said such large-scale deals are "often disruptive."
Novartis posted first-quarter profit that beat expectations, boosted by an exceptional gain from the sale of its blood transfusion test unit.
James West, healthcare analyst at Results Healthcare, says the pharmaceutical sector is "dynamic" and the flurry of deals is likely to continue.